2. Search Result
Search Result
Results for "

striatal

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

4

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2326
    (±)-Anatoxin A fumarate

    		nAChR Neurological Disease
    (±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits Ki values of 1.25 nM and 1.84 μM for binding to putative α4β2-type nAChR and α7-type nAChR in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ 3H]-dopamine release from rat striatal synaptosomes (EC50=134 nM) .
    (±)-Anatoxin A fumarate
  • HY-156772
    GPR88 agonist 2

    		GPR88 Others Neurological Disease
    GPR88 agonist 2 (compound 53) is a potent and brain-penetrantGPR88 agonist with an EC50 value of 14 µM in GPR88 cAMP functional assay .
    GPR88 agonist 2
  • HY-12701A
    U-99194 maleate

    U-99194A; PNU-99194A maleate; JPC-211 maleate

    		 Dopamine Receptor Neurological Disease
    U-99194 maleate is a potent and selective Dopamine3 Receptor (D3 receptor) antagonist. U-99194 maleate also enhances prolactin secretion and striatal dopamine synthesis .
    U-99194 maleate
  • HY-118706
    PD 118440

    		Dopamine Receptor Neurological Disease
    PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .
    PD 118440
  • HY-P4532
    Ac-Leu-Val-Lys-Aldehyde

    		Cathepsin Neurological Disease
    Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC50s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .
    Ac-Leu-Val-Lys-Aldehyde
  • HY-110302
    6'-GNTI dihydrochloride

    		Opioid Receptor Neurological Disease
    6'-GNTI dihydrochloride, a κ-opioid receptor (KOR) agonist, displays bias toward the activation of G protein-mediated signaling over β-arrestin2 recruitment. 6'-GNTI 6'-GNTI dihydrochloride only activates the Akt pathway in striatal neurons .
    6'-GNTI dihydrochloride
  • HY-12294B
    (Rac)-PEAQX

    (Rac)-NVP-AAM077

    		 iGluR Caspase Apoptosis Neurological Disease
    (Rac)-PEAQX is a NMDA receptor agonist. (Rac)-PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
    (Rac)-PEAQX
  • HY-116550
    Piroheptine hydrochloride

    		Dopamine Transporter Neurological Disease
    Piroheptine hydrochloride is an anticholinergic agent to inhibit dopamine uptake. Piroheptine hydrochloride prevents loss of striatal dopamine induced by MPTP (HY-15608). Piroheptine hydrochloride can be used for research in Parkinson .
    Piroheptine hydrochloride
  • HY-118461
    PD 120697

    		Dopamine Receptor Neurological Disease
    PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .
    PD 120697
  • HY-129682
    LY125180

    		5-HT Receptor Dopamine Receptor Adrenergic Receptor Neurological Disease
    LY125180 is a serotonin uptake inhibitor. LY125180 competitively inhibits the uptake of serotonin and norepinephrine by cortical synaptosomes and of dopamine by striatal synaptosomes, with Ki values of 0.06 μM, 2.2 μM and 2.5 μM respectively .
    LY125180
  • HY-120017
    Befloxatone

    MD-370503

    		 Monoamine Oxidase Neurological Disease
    Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC50=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential .
    Befloxatone
  • HY-107674
    bPiDDB

    		nAChR Neurological Disease
    bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC50=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .
    bPiDDB
  • HY-117838
    Phosphodiesterase 10-IN-2

    		Phosphodiesterase (PDE) Neurological Disease
    Phosphodiesterase 10-IN-2 (THPP-4) is an oral active phosphodiesterase 10A (PDE10A) inhibitor with the Ki of 4.5 nM. Phosphodiesterase 10-IN-2 can be used for study of schizophrenia .
    Phosphodiesterase 10-IN-2
  • HY-152170
    bPiDI

    		nAChR Neurological Disease
    bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .
    bPiDI
  • HY-145468
    GPR52 antagonist-1

    		GPR52 Neurological Disease
    GPR52 antagonist-1 (Compound 43) is a GPR52 antagonist with an IC50 of 0.63 μM. GPR52 antagonist-1 reduces mHTT (mutant huntingtin protein) levels by targeting GPR52 and promotes survival of mouse primary striatal neurons .
    GPR52 antagonist-1
  • HY-P1303
    CART(62-76)(human,rat)

    		5-HT Receptor Neurological Disease
    CART(62-76)(human,rat) is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain .
    CART(62-76)(human,rat)
  • HY-W008610
    GBR 12783

    		Dopamine Receptor Neurological Disease
    GBR 12783 is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ 3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 can improve memory performance and increase hippocampal acetylcholine release in rats .
    GBR 12783
  • HY-100968
    GBR 12783 dihydrochloride

    		Dopamine Receptor Neurological Disease
    GBR 12783 dihydrochloride is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ 3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats .
    GBR 12783 dihydrochloride
  • HY-B1124A
    Fipexide hydrochloride
    1 Publications Verification

    		 Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research. Fipexide hydrochloride acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide hydrochloride
  • HY-B1124
    Fipexide
    1 Publications Verification

    		 Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide
  • HY-121810
    LBT-999

    		Dopamine Transporter Others
    LBT-999 is a phenyltropane derivative used for positron emission tomography (PET) exploration of the dopamine transporter (DAT). It has high affinity binding to DAT on rat striatal membranes and human postmortem brain slices in vitro, high uptake in the striatum in rat and baboon models in vivo, and its binding can be blocked by specific compounds.
    LBT-999
  • HY-P1303A
    CART(62-76)(human,rat) TFA

    		5-HT Receptor Neurological Disease
    CART(62-76)(human,rat) TFA is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) TFA can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain .
    CART(62-76)(human,rat) TFA
  • HY-12294
    PEAQX

    NVP-AAM077

    		 Caspase Apoptosis iGluR Neurological Disease
    PEAQX (NVP-AAM077) is an orally active and selective NMDA antagonist, with IC50 values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
    PEAQX
  • HY-156331
    VU6004909

    		mGluR Neurological Disease
    VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC50s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy .
    VU6004909
  • HY-Z0283
    Benzamide

    Benzenecarboxamide; Phenylamide

    		 Endogenous Metabolite PARP Others
    Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
    Benzamide
  • HY-160019
    MTX115325

    		Deubiquitinase Mitophagy Neurological Disease
    MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC50=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC50=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .
    MTX115325
  • HY-105793
    Mazaticol

    		mAChR Neurological Disease
    Mazaticol is an anticholinergic agent. Mazaticol blocks the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol is a potent 3H-QNB and 3H-PZ binding inhibitor, can bind to the M2 receptors with high affinity. Mazaticol exhibits inhibitory effects on dopamine uptake in the striatal nerve terminal. Mazaticol can be used for parkinsonian syndrome research .
    Mazaticol
  • HY-B1124R
    Fipexide (Standard)

    		Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide (Standard) is the analytical standard of Fipexide. This product is intended for research and analytical applications. Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide (Standard)
  • HY-10435
    SKF-82958

    (±)-SKF-82958; Chloro-APB

    		 Dopamine Receptor Neurological Disease
    SKF-82958 ((±)-SKF 82958) is a dopamine D1 receptor full agonist (K0.5=4 nM), displays selective for D1 over D2 receptors (K0.5=73 nM). SKF-82958 induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC50=491 nM) .
    SKF-82958
  • HY-10435A
    SKF-82958 hydrobromide
    3 Publications Verification

    (±)-SKF-82958 hydrobromide; Chloro-APB hydrobromide

    		 Dopamine Receptor Neurological Disease
    SKF-82958 ((±)-SKF 82958) hydrobromide is a dopamine D1 receptor full agonist (K0.5=4 nM), displays selective for D1 over D2 receptors (K0.5=73 nM). SKF-82958 hydrobromide induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC50=491 nM) .
    SKF-82958 hydrobromide
  • HY-12294A
    PEAQX tetrasodium hydrate
    5 Publications Verification

    NVP-AAM077 tetrasodium hydrate

    		 Apoptosis Caspase iGluR Neurological Disease
    PEAQX tetrasodium hydrate (NVP-AAM077 tetrasodium hydrate) is a tetrasodium hydrate of PEAQX (HY-12294). PEAQX tetrasodium hydrate is an orally active and selective NMDA antagonist, with IC50 values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX tetrasodium hydrate can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
    PEAQX tetrasodium hydrate
  • HY-124591
    TC-2153

    		5-HT Receptor Monoamine Oxidase Neurological Disease
    TC-2153 is a selective inhibitor of striatal-enriched protein tyrosine phosphatase (STEP), with psychotropic activity and low acute toxicity. TC-2153 increases the expression of brain-derived neurotropic factor (BDNF) in the brain. And it decreases MAOA and 5-HT1A receptors mRNA level in midbrain. TC-2153 also inhibits 5-HT2A receptor-mediated signaling .
    TC-2153
  • HY-Z0283R
    Benzamide (Standard)

    		Endogenous Metabolite PARP Others
    Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
    Benzamide (Standard)
  • HY-P1206
    CH 275

    		Somatostatin Receptor Neurological Disease
    CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst1) with a Ki of 52 nM . CH 275 acts as a potent and selective sst1 agonist (IC50=30.9 nM) and also displays IC50 values of 345 nM, >1 μM, >10 μM, >10 μM for human sst3, sst4, sst2 and sst5, respectively . CH 275 can be used for the research of alzheimer’s disease .
    CH 275
  • HY-116450
    TISCH

    		Dopamine Receptor Neurological Disease
    TISCH is a potent and selective iodinated ligand with high affinity and selectivity for CNS D1 dopamine receptors. TISCH showed a Kd value of 0.205 nM in rat striatal tissue, indicating its effectiveness in biological activity. TISCH is able to easily cross the blood-brain barrier and show distribution in specific areas with D1 receptor density. TISCH is considered to be useful as a pharmacological tool for characterizing D1 dopamine receptors. When labeled with I-123, TISCH has the potential to be used as an in vivo imaging agent for CNS D1 dopamine receptors .
    TISCH
  • HY-171328
    RG-15

    		Dopamine Receptor Neurological Disease
    RG-15 is the orally active antagonist for dopamine receptor that exhibits goof affinity to human D2 receptor and human D3 receptor with pKi of 8.23 and 10.49. RG-15 inhibits dopamine-stimulated [ 35S]GTPγS binding with IC50 of 21.2 nM (rat striatal membranes), 36.7 nM (mouse A9 cells expressing human D2L receptors) and 7.2 nM (CHO cells expressing human D3 receptors). RG-15 increases the turnover and biosynthesis of dopamine in mouse striatum and olfactory bulb, exhibiting antipsychotic activity .
    RG-15
  • HY-101343
    RS 39604

    		5-HT Receptor Neurological Disease
    RS 39604 is a potent, selective, and orally active 5-HT4 receptor antagonist with a pKi of 9.1 in guinea pig striatal membranes. RS 39604 displays a low affinity (pKi<6.5) for 5-HT1A, 5-HT2C, 5-HT3, α1c, D1, D2, M1, M2, AT1, B1 and opioid mu receptors and moderate affinity for δ1, (pKi=6.8) and δ2 (pKi=7.8) sites .
    RS 39604
  • HY-138232
    Lys-psi(CH2NH)-Trp(Nps)-OMe

    LTNAM

    		 Aminopeptidase Neurological Disease
    Lys-psi(CH2NH)-Trp(Nps)-OMe is a lysine-tryptophan (Nps) pseudodipeptide analog. It is obtained by replacing the peptide bond in the Lys-Trp(Nps) molecule with an aminomethylene bond and has analgesic activity. Lys-psi(CH2NH)-Trp(Nps)-OMe induces a dose-dependent and naloxone-reversible analgesia after intracerebroventricular administration in mice, and its analgesic effect lasts longer than that of the original compound. It protects methionine enkephalin from degradation in rat striatal slices and binds to low-dose opioid peptides to produce analgesia. Lys-psi(CH2NH)-Trp(Nps)-OMe effectively inhibits brain aminopeptidase activity both in vitro and in vivo. The enhanced resistance of this pseudodipeptide to proteolysis may explain its prolonged analgesic activity.
    Lys-psi(CH2NH)-Trp(Nps)-OMe